Telix Pharmaceuticals Limited (ASX:TLX)

Telix Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2021	Dec 31, 2020
Revenue	803.79	516.55	332.98	5.52	4.01
Revenue Growth (YoY)	55.61%	55.13%	5930.95%	37.53%	-
Cost of Revenue	377.36	180.39	123.45	4.63	1.56
Gross Profit	426.44	336.16	209.53	0.89	2.46
Selling, General & Admin	237.15	157.94	89.38	24.64	6.87
Depreciation & Amortization Expenses	-	-	-	-	3.76
Research & Development	171.25	127.93	85.32	34.97	17.78
Other Operating Expenses	11.74	4.89	-23.83	4.7	5.18
Operating Income	29.78	55.18	11.01	-54.69	-31.13
Interest Income	5.83	7.18	0.67	-	-
Interest Expense	-40.87	-24.44	-9.09	-3.79	-1.34
Other Non-Operating Income (Expense)	-	-	-	-	7.53
Total Non-Operating Income (Expense)	-35.04	-17.26	-8.41	-3.79	6.2
Pretax Income	-5.27	37.92	2.59	-58.49	-36.91
Provision for Income Taxes	1.86	4.23	-1.61	-0.03	-2.35
Net Income	-7.13	33.69	4.21	-58.52	-34.57
Net Income to Common	-7.13	33.69	4.21	-58.52	-34.57
Net Income Growth	-	700.50%	-	-	-
Shares Outstanding (Basic)	338	331	319	282	257
Shares Outstanding (Diluted)	338	345	324	282	257
Shares Change (YoY)	-2.12%	6.64%	14.71%	9.69%	-
EPS (Basic)	-0.02	0.10	0.01	-0.21	-0.13
EPS (Diluted)	-0.02	0.10	0.01	-0.21	-0.13
EPS Growth	-	650.77%	-	-	-
Free Cash Flow	-42.99	18.37	7.97	-44.1	1.32
Free Cash Flow Growth	-	130.64%	-	-	-
Free Cash Flow Per Share	-0.13	0.05	0.02	-0.16	0.01
Gross Margin	53.05%	65.08%	62.93%	16.13%	61.17%
Operating Margin	3.70%	10.68%	3.31%	-990.61%	-775.37%
Profit Margin	-0.89%	6.52%	1.26%	-1059.90%	-861.06%
FCF Margin	-5.35%	3.56%	2.39%	-798.67%	32.84%
EBITDA	51.19	60.46	15.16	-54.69	-31.13
EBITDA Margin	6.37%	11.70%	4.55%	-990.61%	-775.37%
EBIT	29.78	55.18	11.01	-54.69	-31.13
EBIT Margin	3.70%	10.68%	3.31%	-990.61%	-775.37%
Effective Tax Rate	-35.30%	11.16%	-62.22%	0.06%	6.36%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.